Antibiotic Selection for Cellulitis
For typical nonpurulent cellulitis in an otherwise healthy adult, start with a beta-lactam antibiotic such as cephalexin 500 mg four times daily or penicillin, treating for 5 days if clinical improvement occurs. 1, 2, 3
Initial Assessment: Purulent vs. Nonpurulent
The critical first step is determining whether the cellulitis is purulent (associated with drainage, exudate, or abscess) or nonpurulent (classic spreading erythema without purulence):
Nonpurulent Cellulitis (Most Common)
First-line therapy: Target beta-hemolytic streptococci with:
Duration: 5 days is as effective as 10 days if clinical improvement occurs by day 5 3
MRSA coverage is NOT routinely needed for typical nonpurulent cellulitis 1, 2, 3. The IDSA guidelines explicitly state that empirical MRSA coverage should only be added if the patient fails to respond to beta-lactam therapy or presents with systemic toxicity 1, 2. A prospective study demonstrated 96% success with beta-lactams alone (cefazolin/oxacillin), confirming MRSA is an uncommon cause of typical cellulitis 3.
Purulent Cellulitis
- Empirical MRSA coverage IS recommended pending cultures 1, 2
- Streptococcal coverage is likely unnecessary 1, 2
- Options include clindamycin, TMP-SMX, or doxycycline 1, 2
Penicillin Allergy Considerations
For patients with documented penicillin allergy:
Non-immediate hypersensitivity: Cephalosporins (cefazolin, cephalexin) are safe options 4. Recent evidence shows that in the absence of cross-reactivity alerts, cephalosporins are prescribed 13 times more frequently to penicillin-allergic patients without adverse outcomes 5.
Immediate hypersensitivity or true IgE-mediated allergy:
Critical caveat: Documented penicillin allergy increases risk of MRSA (adjusted HR 1.69) and C. difficile (adjusted HR 1.26) due to increased use of broad-spectrum alternatives 6. This underscores the importance of verifying true penicillin allergy before avoiding beta-lactams.
When to Add MRSA Coverage
Add empirical MRSA coverage in nonpurulent cellulitis ONLY if:
- Failure to respond to beta-lactam therapy after 48-72 hours 1, 2
- Systemic toxicity present 1, 2
- Penetrating trauma, especially injection drug use 3
- Concurrent purulent drainage 3
- Evidence of MRSA infection elsewhere 3
If dual coverage needed (streptococci + MRSA):
- Clindamycin alone (covers both) 1, 2
- TMP-SMX or doxycycline PLUS a beta-lactam (amoxicillin, cephalexin) 1, 2
- Linezolid alone 1, 2
Common Pitfalls
Avoid these errors:
Overusing MRSA coverage: A recent study showed TMP-SMX plus cephalexin was no more effective than cephalexin alone for pure cellulitis 3. Broad-spectrum antibiotics were used in two-thirds of hospitalized cellulitis patients despite no difference in failure rates 3.
Bilateral cellulitis is rare - consider alternative diagnoses like venous stasis dermatitis 7, 8
Don't culture typical cellulitis - blood cultures and tissue aspirates have poor yield and are unnecessary unless severe systemic features, malignancy, neutropenia, or unusual exposures are present 3
Avoid rifampin as monotherapy or adjunctive therapy for cellulitis 1, 2
Hospitalized/Severe Cases
For hospitalized patients requiring IV therapy:
- Nonpurulent cellulitis: Cefazolin 1 g IV every 8 hours, modify to MRSA-active therapy only if no clinical response 1, 2
- If MRSA coverage needed: Vancomycin 30 mg/kg/day IV in 2 divided doses, linezolid 600 mg IV/PO twice daily, or daptomycin 4 mg/kg IV once daily 1, 2
- Duration: 7-14 days based on clinical response 1, 2
The evidence strongly supports narrow-spectrum beta-lactam therapy as first-line for typical cellulitis, reserving MRSA-active agents for specific clinical scenarios to minimize antimicrobial resistance and adverse effects.